Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Syndax Pharmaceuticals reported a strong financial performance with a 224% year-over-year revenue increase, driven by demand for Revuforj and Niktimvo. The Q&A highlighted positive market dynamics, such as high investigator interest in Niktimvo for IPF and potential market leadership for Revuforj. Despite some uncertainties in guidance, the overall sentiment is positive due to strong revenue growth, promising pipeline developments, and robust financial health, suggesting a positive stock price movement.
Key Financial Performance
Total Revenue $64.9 million, up 224% year-over-year. This growth was driven by strong demand for Revuforj and Niktimvo.
Revuforj Net Revenue $48.9 million, up 144% year-over-year. Growth was attributed to increased adoption in NPM1 and KMT2A indications, as well as expanding prescriber base and payer coverage.
Niktimvo Net Revenue $55 million, reflecting consistent new patient starts and solid persistency. Growth was partially offset by natural attrition among later-line patients.
Collaboration Revenue from Niktimvo $15.9 million, a significant increase from the $0.2 million collaboration loss in the same period last year. This was due to growing sales and a stable expense base.
Cash, Cash Equivalents, and Marketable Securities $352.1 million as of March 31, 2026, providing a robust balance sheet to support ongoing investments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revuforj Sales: Generated $49 million in net revenue in Q1 2026, driven by strong adoption in NPM1 and KMT2A indications. Demonstrated double-digit quarter-over-quarter growth.
Niktimvo Sales: Delivered $55 million in net revenue in Q1 2026, reflecting consistent new patient starts and increasing uptake in third-line chronic GVHD.
Market Expansion for Revuforj: Expanded into relapsed/refractory NPM1 mutated AML market, with less than 10% of the 4,500 annual incident population currently treated with menin inhibitors. Positioned as a leader in NPM1 and KMT2A markets.
Market Expansion for Niktimvo: Captured 32% of the third-line plus chronic GVHD market within one year of launch, with increasing adoption in third-line patients.
Operational Efficiency in Revuforj: Achieved nearly perfect payer coverage (97% of covered lives) and expanded prescriber base to over 500 accounts.
Operational Efficiency in Niktimvo: Strong prescriber base with virtually every bone marrow transplant center in the U.S. prescribing Niktimvo. Maintained a collaboration revenue margin of 25%-30%.
Strategic Shift in Revuforj: Focused on advancing pivotal frontline trials for revumenib to establish leadership in menin inhibition across acute leukemia treatment continuum.
Strategic Shift in Niktimvo: Preparing for Phase II data readouts in idiopathic pulmonary fibrosis (IPF) and newly diagnosed chronic GVHD patients treated with Niktimvo plus Jakafi, targeting multibillion-dollar markets.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Short-term impact of high transplant rates: The robust transplant rate for KMT2A patients using Revuforj has a short-term impact on the business as many patients temporarily pause therapy to proceed to transplant. This obscures the growth of patients returning to therapy post-transplant.
Natural attrition in Niktimvo patient cohort: There is natural attrition among the large cohort of predominantly later-line patients who started Niktimvo during its initial launch phase, which impacts revenue growth.
Competition in menin inhibitor market: The launch of a second menin inhibitor for adult NPM1 patients introduces competitive pressures, although Revuforj maintains a strong market position.
Regulatory and clinical trial risks: The company is advancing pivotal trials for Revuforj and Niktimvo in new indications, which carry inherent risks related to regulatory approval and clinical trial outcomes.
Economic and weather-related disruptions: Severe winter storms in the first quarter impacted patient access to infusion drugs, temporarily affecting revenue for both Revuforj and Niktimvo.
Dependency on payer coverage and physician adoption: While Revuforj has nearly perfect payer coverage, its success depends on continued physician adoption and preference over competing therapies.
Attrition in chronic GVHD treatment: Niktimvo faces challenges in maintaining long-term treatment durations, particularly as the patient mix shifts towards less advanced disease stages.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects continued growth in revenue from Revuforj and Niktimvo, driven by increased adoption in NPM1 and KMT2A markets, as well as extended treatment durations and post-transplant therapy.
Pipeline Development: Syndax is advancing pivotal frontline trials for revumenib, aiming to be the first to deliver pivotal frontline data for a menin inhibitor. The company anticipates multiple data readouts throughout 2026, including real-world evidence, post-transplant maintenance data, and updates from various trials.
Market Expansion: Revuforj is positioned to expand into the NPM1 market and continue penetrating the KMT2A market, with a long-term goal of unlocking a $5 billion-plus market opportunity. Niktimvo is expected to grow in the third-line chronic GVHD market and potentially expand into IPF and frontline chronic GVHD markets.
Financial Outlook: The company is on track to reach profitability with stable expenses and growing revenue. Guidance for total R&D and SG&A expenses in 2026 remains at approximately $400 million, excluding $50 million in non-cash stock compensation expense.
Upcoming Data Readouts: Key data readouts are expected in the second quarter and throughout 2026, including updates on revumenib in various trials and Niktimvo in IPF and chronic GVHD.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What should we look for in the upcoming multicenter real-world study on Revuforj?
A:The study will provide broad coverage across genetic subtypes, including NUP98. It will highlight the extensive use of Revuforj in combination therapies, the number of patients progressing to transplant, and the ability to get patients onto maintenance therapy.
Q:Can you quantify the headwind to revenue or patients due to the KMT2A population going to transplant?
A:Approximately 50% of the KMT2A population is going to transplant. The company expects to exceed 50% penetration in the KMT2A market this year, with maintenance being a significant growth driver. Patients returning post-transplant take an average of 3-4 months, with some taking 6 months or more.
Q:What is gating the penetration of NPM1, and how does the FLT3 combo data impact this?
A:NPM1 penetration is still in the early stages. The market is different from KMT2A, with older patients and more complex co-mutations. FLT3 combo data expected later this year could be important for increasing penetration.
Q:What is the time course of responses in GVHD, and is 26-week duration sufficient in IPF?
A:The 26-week duration is considered sufficient for IPF as it provides enough time to detect differences while being statistically rigorous. Annualized rates of FVC decline will be reported using FDA-approved models.
Q:When will the transplant maintenance dynamic flip from a headwind to a tailwind?
A:The company expects the transplant rate to stabilize at around 50%, with 70-80% of patients restarting maintenance. This dynamic is expected to become a tailwind as more patients return post-transplant, though the timing is uncertain.
Q:Will the Phase II axa/rux combo trial support a compendia listing for frontline GVHD?
A:If the trial shows a meaningful improvement in response rates (e.g., 60% compared to the 40% benchmark), it could inform clinical practice and potentially support a compendia listing.
Q:What is the progress in the first-line AML Phase III trials?
A:The trials are progressing well, with EVOLVE-2 enrolling patients for nearly a year and REVEAL ND making progress in site activations and patient enrollment. The company expects to be first to market in the frontline setting.
Q:What is the investigator and payer interest in Niktimvo's antifibrotic potential for IPF?
A:There is high investigator interest due to the unmet need in IPF. The market opportunity is significant, with approximately 150,000 patients in the U.S. The drug could be a game-changer if it shows meaningful efficacy and safety.
Q:What are the commercial dynamics between Revuforj and its competitor?
A:Revuforj has a better profile and broader advantages, according to physicians. The presence of a competitor raises awareness of the menin class, which could benefit Revuforj as the market leader.
Q:What is the status of the MAXPIRe study for IPF?
A:The study is well-powered and aims to show a 40% improvement in the rate of FVC decline. It is designed to inform a Phase III program and is expected to report data in Q4.
Q:What is the potential of NUP98 as an expansion opportunity for Revuforj?
A:NUP98 represents about 5% of AML and is an area of high unmet need. The company plans to present additional data this year and may consider submitting for NCCN guidelines.
Q:Review of Unclear Management Responses
A:Management avoided providing specific revenue guidance for 2026, citing the early stage of the NPM1 launch and competition. They also did not provide exact numbers for the absolute number of patients returning post-transplant or detailed statistical assumptions for the MAXPIRe study.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AML
IPF patient
NPM patient
NUP
Phase
Revuforj
Slide
activity
axatilimab
base
class
collaboration
combination
disease
drug
duration therapy
efficacy
enrollment
evidence
factor
frontline
launch
leukemia
line
macrophage
market
medicine
menin inhibitor
monocyte
number patient
patient therapy
physician
population
potential
program
rate
term
transplant
treatment
trial revumenib
SNDX Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
Positive4-30
Syndax Pharmaceuticals reported a strong financial performance with a 224% year-over-year revenue increase, driven by demand for Revuforj and Niktimvo. The Q&A highlighted positive market dynamics, such as high investigator interest in Niktimvo for IPF and potential market leadership for Revuforj. Despite some uncertainties in guidance, the overall sentiment is positive due to strong revenue growth, promising pipeline developments, and robust financial health, suggesting a positive stock price movement.
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-12
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary highlights strong financial performance with revenue and net income growth, a focus on strategic initiatives, and positive market trends in oncology. Although no specific risks were discussed, the company's optimistic outlook on revenue expectations and strategic partnerships suggests a positive sentiment. The market cap of $1.7 billion indicates moderate sensitivity to these factors, leading to a positive prediction for stock movement in the short term.
Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
SNDX Slides
SNDX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
